Vera Therapeutics (VERA) Total Debt (2021 - 2023)

Vera Therapeutics has reported Total Debt for 3 years, with the latest figure at $3.1 million in Q1 2023.

• For the quarter ending Q1 2023, Total Debt fell 53.77% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2023 stood at $3.1 million (down 53.77% YoY), and the FY2022 full-year result was $2.8 million, down 53.84% from the prior year.
• Total Debt for Q1 2023 stood at $3.1 million, up from $2.8 million in the prior quarter.
• The five-year high for Total Debt was $6.7 million in Q2 2022, with the low at $994000.0 in Q3 2021.
• Historically, Total Debt has averaged $4.6 million across 3 years, with a median of $6.0 million in 2022.
• The largest YoY upside for Total Debt was 504.02% in 2022 against a maximum downside of 53.84% in 2022.
• Vera Therapeutics' Total Debt stood at $6.0 million in 2021, then plunged by 53.84% to $2.8 million in 2022, then rose by 10.43% to $3.1 million in 2023.
• The last three Total Debt figures came in at $3.1 million (Q1 2023), $2.8 million (Q4 2022), and $6.0 million (Q3 2022), per Business Quant data.